Download PDF
Thromb Haemost 2012; 108(04): 796-798
DOI: 10.1160/TH12-03-0136
Letters to the Editor
Schattauer GmbH

Management of delivery with FVIII/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodies

Mónica Martín-Salces
1   Haematology Department, Hospital Universitario La Paz, Madrid, Spain
,
Víctor Jiménez-Yuste
1   Haematology Department, Hospital Universitario La Paz, Madrid, Spain
,
María Teresa Álvarez-Román
1   Haematology Department, Hospital Universitario La Paz, Madrid, Spain
,
Isabel Rivas-Pollmar
1   Haematology Department, Hospital Universitario La Paz, Madrid, Spain
,
Ana Rodríguez de la Rúa
1   Haematology Department, Hospital Universitario La Paz, Madrid, Spain
› Author Affiliations
Further Information

Publication History

Received: 02 March 2012

Accepted after major revision: 27 June 2012

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Federici AB. Clinical and molecular markers of inherited VWD type 3: are deletions of the VWF gene associated with alloantibodies to VWF?. J Thromb Haemost 2008; 06: 1726-1728.
    CrossrefPubMedGoogle Scholar
  • 2 Shelton-Inloes BB, Chehab FF, Mannucci PM. et al. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459-1465.
    CrossrefPubMedGoogle Scholar
  • 3 Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-1239.
    CrossrefPubMedGoogle Scholar
  • 4 Bergamaschini L, Mannucci PM, Federici AB. et al. Posttransfusion anaphylactic reactions in a patient with severe von Willebr and disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348-355.
    PubMedGoogle Scholar
  • 5 Franchini M, Gandini G, Giuffrida A. et al. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia 2008; 14: 645-646.
    CrossrefPubMedGoogle Scholar
  • 6 Grossmann RE, Geisen U, Schwender S. et al. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000; 83: 633-634.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Boyer-Neumann C, Dreyfus M, Wolf M. et al. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Wille-brand disease. J Thromb Haemost 2003; 01: 190-192.
    CrossrefPubMedGoogle Scholar
  • 8 Liu S, Liston RM, Joseph KS. et al. Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term. CMAJ 2007; 176: 455-460.
    CrossrefPubMedGoogle Scholar
  • 9 Tout H, Obert B, Houllier A. et al. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thromb Haemost 2000; 83: 274-281.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Franchini M, Lippi G, Montagnana M. et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis 2009; 20: 225-229.
    CrossrefPubMedGoogle Scholar
  • 11 Ciavarella N, Schiavoni M, Valenzano E. et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 (Suppl. 01) 150-154.
    PubMedGoogle Scholar